Navigation Links
NUCRYST Announces First Quarter 2008 Financial Results
Date:5/6/2008

ped to Smith & Nephew. The increase was offset by the recognition during the quarter of $1.1 million of a $4.5 million manufacturing cost rebate payable to Smith & Nephew under our supply agreement.

Net loss for the first quarter of 2008 was $2.2 million, or $0.12 per share, compared to a net loss of $1.9 million, or $0.10 per share, reported for the first quarter of 2007.

Gross margin on revenues was 21% and 40% for the first quarters of 2008 and 2007, respectively, with the decrease attributable primarily to the $1.1 million manufacturing cost rebate recognized as a reduction to wound care product revenue as compared to no such amount being recognized in the first quarter of 2007. Gross margin excluding the manufacturing cost rebate was 35% and 40% for the first quarters of 2008 and 2007, respectively. We recognize manufacturing revenue when we ship product to Smith & Nephew and recognize royalty income when Smith & Nephew sells our products to its customers. Consequently, our gross margin percent may vary from period to period due to differences in timing of when we ship product to Smith & Nephew and when Smith & Nephew sells product to its customers. In the three months ended March 31, 2008, we shipped higher volumes of Acticoat(TM) products to Smith & Nephew as compared to the three months ended March 31, 2007.

Manufacturing costs for the first quarter of 2008 totaled $4.1 million, up $1.0 million from the same period in 2007, which reflects increased shipments of wound care products to Smith & Nephew.

Research and development spending for the first quarter of 2008 totaled $1.5 million compared to $2.0 million for the comparable period in 2007. The decrease is primarily the result of reductions that the Company has made to its research operations and staff to conserve cash and control expenses.

General and administrative expenses totaled $2.4 million for the first quarter of 2008, compared with $1.8 million in the same period
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. NUCRYST Announces Management Realignment and R&D Portfolio Change
2. NUCRYST Announces Senior Management Change
3. NUCRYST Pharmaceuticals announces year-end results
4. NUCRYST Pharmaceuticals announces 2007 third quarter results
5. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
6. NUCRYST and Smith & Nephew Revise Agreements
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Bank of America Healthcare Conference
8. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
9. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
10. Rigel Announces First Quarter 2008 Financial Results
11. BioForm Medical Announces Extension of Lock-Up Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Calif., Dec. 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company ... aging, today announced that shareholders had approved all three resolutions that the Company had proposed ... as follows: , , Description of ... Votes ... For ...
(Date:12/15/2009)... will be donated to the Lupus Foundation of America ... WASHINGTON, Dec. 15 Julian Lennon, son of ... released their new digital single, "LUCY," to raise funds ... March 15, 2010, 100 percent of the proceeds from ... Lupus Foundation of America (LFA), and the Saint Thomas, ...
(Date:12/15/2009)... lower dementia risk, research finds , , TUESDAY, Dec. 15 ... hormone that regulates appetite, may guard against Alzheimer,s disease, ... years this may be one of many agents that ... said senior study author Dr. Sudha Seshadri, an associate ... "Or it may be one of many markers that ...
(Date:12/15/2009)... delivered ,, WASHINGTON, Dec. 15 ... that healthcare reform does not override the prostate ... in 37 states. ,, Prostate cancer screening is ... and individuals who are identifiable as high risk, ... a family history of prostate cancer. The American ...
(Date:12/15/2009)... 15 Team In Training (TNT), The ... charity sports training program, has reached a remarkable ... cancer research and patient services. ,, For more ... charity endurance sports training program, preparing amateurs and ... triathlon, 100-mile century cycle ride or hike adventure. ...
Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3
... may be the answer in developing ... ... Cancer,Prevention (ACCP), a partnership of five international public health,research organizations, today announced ... 20 countries in Africa,Asia, and Latin America. At the top of the ...
... March 5 The Pharmaceutical,Research and Manufacturers of ... in the research pipeline for neurological diseases. The ... new,medicines to help treat neurological diseases., "We ... its particular,relevance to the health of this city,s ...
... the one in three adults who fail to take their ... everyone else who occasionally forgets: a sensor necklace that records ... and reminds the user if any doses are being missed. ... but so is taking the medication at the wrong time, ...
... perspective on empowered consumers at,Best Practices Conference and ... Most of the discussion,surrounding health care reform ... wield enormous potential power for changing an,onerous health ... Empowering consumers to become "smart patients" will ...
... anchor ... depth, ANDOVER, ... Endoscopy Division today announced the launch of the,BIORAPTOR 2.3 PK Suture Anchor ... featured at Smith & Nephew Endoscopy,s booth,at the American Academy of Orthopedic ...
... 5 The Chartis Group, a leading,healthcare advisory ... Pamela Damsky, James Karpook and Gregory Maddrey to ... leading healthcare,organizations in advancing their strategic, organizational and ... tremendous asset to our clients and our,firm. Greg, ...
Other Medicine News:Health News:New Findings Support Alternatives to Pap Test 2Health News:New Findings Support Alternatives to Pap Test 3Health News:New Findings Support Alternatives to Pap Test 4Health News:Report on 547 New Medicines in Development for Neurological Disorders Released in San Antonio 2Health News:Report on 547 New Medicines in Development for Neurological Disorders Released in San Antonio 3Health News:Sensor necklace aims to increase elderly and clinical trial participant drug compliance 2Health News:Sensor necklace aims to increase elderly and clinical trial participant drug compliance 3Health News:Sensor necklace aims to increase elderly and clinical trial participant drug compliance 4Health News:Cultivating the Smart Patient: Author and RealAge Founder Michael F. Roizen, MD to Present Keynote at URAC Conference 2Health News:Cultivating the Smart Patient: Author and RealAge Founder Michael F. Roizen, MD to Present Keynote at URAC Conference 3Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 3Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 4Health News:The Chartis Group Elects New Partners: Four Healthcare Industry Experts Promoted to Principal 2Health News:The Chartis Group Elects New Partners: Four Healthcare Industry Experts Promoted to Principal 3
(Date:12/15/2009)... -- Cumberland Pharmaceuticals Inc. ( CPIX) ... results for a patient preference study evaluating Kristalose ... laxative packaged as a crystalline powder, compared to ... the only prescription-strength laxative available in pre-measured powder ... a recent diagnosis of chronic constipation were administered ...
(Date:12/15/2009)... healthcare providers who have already immunized patients most ... virus may now offer the vaccine to anyone ... today. ,, Pennsylvania is expanding the H1N1 ... doses of vaccine have been allocated to healthcare ... priority groups. ,, "Many certified providers have already ...
(Date:12/15/2009)... LAKE ZURICH, Ill., Dec. 15 Fenwal ... improving blood collection, separation, safety and availability, announced ... has granted Fenwal approval to market InterSol ® ... InterSol ® solution is a specialized product ... donated platelets, a vital blood component used to ...
Breaking Medicine Technology:Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 1New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 2New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 3New Online Tutorials for IMG IMG M NCBI Viral Genomes and VBRC 60043 4Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 1Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 2Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 3Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 4Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 5Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 6Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 7Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 8Study shows how carbon nanotubes can affect lining of the lungs 10514 1Study shows how carbon nanotubes can affect lining of the lungs 10514 2
... total funding expected by year,s end, NEW ... pluripotent stem cell technology are among the cutting-edge,approaches ... J.,Fox Foundation,s Rapid Response Innovation Awards 2008. As ... a cure for PD, the,Foundation has awarded $1.1 ...
... Echo Therapeutics,(OTC Bulletin Board: ECTE) today announced ... Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM),System in ... Diabetes. Echo,s non-invasive,Symphony tCGM System consists of ... the Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free ...
Other Medicine Technology:Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008 2Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4
... autoLog™ Autotransfusion System processes blood collected ... washed red blood cells for return ... time. This is achieved with only ... innovative bowl design, coupled with sophisticated ...
The hipGRIP® is a twenty piece modular lateral positioning system which provides positive pelvis control with an innovative positioning system....
The Simpulse®VariCare™ System provides an innovative system for enhanced wound management which emphasizes performance, simplicity, safety, value, and support....
... staples are especially useful in ... including anterior cruciate reconstruction. They ... fixation, tendon and ligament repair ... Four sizes are available, in ...
Medicine Products: